Neurogene Inc. — Director's Dealing 2021

May 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Neoleukin Therapeutics, Inc. (NLTX)
CIK: 0001404644
Period of Report: 2021-05-11

Reporting Person: Noonberg Sarah B. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-11	Stock Option (Right to Buy)	$11.40	A	25000	Acquired	2031-05-10	Common Stock (25000)	Direct

Footnotes

F1: The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.